Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 12 | 2017 | 259 | 2.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2019 | 145 | 1.100 |
Why?
|
| Anti-Asthmatic Agents | 5 | 2013 | 39 | 0.720 |
Why?
|
| Muscle, Smooth | 7 | 2010 | 68 | 0.580 |
Why?
|
| Exercise Therapy | 1 | 2019 | 270 | 0.550 |
Why?
|
| Trachea | 5 | 2010 | 52 | 0.440 |
Why?
|
| Pharmacogenetics | 1 | 2010 | 29 | 0.360 |
Why?
|
| Dinoprostone | 2 | 2010 | 31 | 0.350 |
Why?
|
| Interleukin-1 | 1 | 2005 | 33 | 0.260 |
Why?
|
| Patient Care | 1 | 2005 | 30 | 0.250 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 3 | 2010 | 19 | 0.250 |
Why?
|
| Bronchoscopy | 3 | 2017 | 47 | 0.250 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2012 | 122 | 0.240 |
Why?
|
| Humans | 23 | 2019 | 32005 | 0.230 |
Why?
|
| Clinical Trials as Topic | 3 | 2010 | 301 | 0.230 |
Why?
|
| Lung | 1 | 2005 | 249 | 0.220 |
Why?
|
| Respiratory Function Tests | 5 | 2019 | 100 | 0.220 |
Why?
|
| Bronchodilator Agents | 3 | 2013 | 49 | 0.220 |
Why?
|
| Scopolamine Derivatives | 2 | 2013 | 5 | 0.210 |
Why?
|
| Protein Kinase C | 3 | 2007 | 31 | 0.200 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 881 | 0.200 |
Why?
|
| Glucocorticoids | 3 | 2010 | 146 | 0.170 |
Why?
|
| Membrane Proteins | 3 | 2007 | 256 | 0.170 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2010 | 72 | 0.170 |
Why?
|
| Quercetin | 1 | 2019 | 8 | 0.160 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2019 | 7 | 0.160 |
Why?
|
| Eosinophils | 2 | 2013 | 29 | 0.160 |
Why?
|
| Albuterol | 3 | 2013 | 19 | 0.160 |
Why?
|
| Ambulatory Care | 1 | 2019 | 108 | 0.160 |
Why?
|
| Self Care | 1 | 2019 | 144 | 0.150 |
Why?
|
| Exercise Tolerance | 1 | 2019 | 125 | 0.150 |
Why?
|
| Patient Selection | 1 | 2019 | 276 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 3 | 2012 | 407 | 0.140 |
Why?
|
| Cells, Cultured | 6 | 2010 | 833 | 0.140 |
Why?
|
| Receptors, Leukotriene | 2 | 2007 | 3 | 0.140 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2010 | 210 | 0.130 |
Why?
|
| Cytokines | 2 | 2007 | 256 | 0.130 |
Why?
|
| Sputum | 1 | 2013 | 15 | 0.110 |
Why?
|
| Neutrophils | 1 | 2013 | 106 | 0.110 |
Why?
|
| Spirometry | 1 | 2011 | 27 | 0.100 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2008 | 85 | 0.100 |
Why?
|
| T-Lymphocytes | 1 | 2011 | 124 | 0.090 |
Why?
|
| Cholinergic Antagonists | 1 | 2010 | 10 | 0.090 |
Why?
|
| Cell Proliferation | 2 | 2010 | 604 | 0.090 |
Why?
|
| Disease Management | 1 | 2011 | 126 | 0.090 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2010 | 5 | 0.090 |
Why?
|
| Interleukin-5 | 1 | 2010 | 5 | 0.090 |
Why?
|
| Th2 Cells | 1 | 2010 | 9 | 0.090 |
Why?
|
| Proton Pump Inhibitors | 1 | 2010 | 12 | 0.090 |
Why?
|
| Disease Susceptibility | 1 | 2010 | 57 | 0.090 |
Why?
|
| Immunomodulation | 1 | 2010 | 32 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2010 | 36 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2010 | 43 | 0.090 |
Why?
|
| Gastroesophageal Reflux | 1 | 2010 | 24 | 0.090 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2010 | 47 | 0.090 |
Why?
|
| Disease Outbreaks | 1 | 2010 | 43 | 0.090 |
Why?
|
| Disease Progression | 1 | 2011 | 594 | 0.080 |
Why?
|
| Influenza Vaccines | 1 | 2010 | 78 | 0.080 |
Why?
|
| Androstadienes | 1 | 2008 | 17 | 0.080 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2008 | 30 | 0.080 |
Why?
|
| G-Protein-Coupled Receptor Kinase 3 | 1 | 2008 | 3 | 0.080 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2008 | 4 | 0.080 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2008 | 4 | 0.080 |
Why?
|
| Vitamin D | 1 | 2010 | 184 | 0.080 |
Why?
|
| Influenza, Human | 1 | 2010 | 122 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 246 | 0.080 |
Why?
|
| Mitogens | 1 | 2007 | 2 | 0.080 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2007 | 40 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 324 | 0.070 |
Why?
|
| Signal Transduction | 2 | 2008 | 682 | 0.070 |
Why?
|
| Muscle Contraction | 1 | 2007 | 114 | 0.070 |
Why?
|
| Phospholipases A2 | 1 | 2005 | 20 | 0.070 |
Why?
|
| Microsomes | 1 | 2005 | 13 | 0.070 |
Why?
|
| Cytosol | 1 | 2005 | 25 | 0.070 |
Why?
|
| Receptors, Prostaglandin E | 1 | 2005 | 4 | 0.070 |
Why?
|
| Phospholipases A | 1 | 2005 | 26 | 0.070 |
Why?
|
| Cyclooxygenase 1 | 1 | 2005 | 22 | 0.070 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 31 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2011 | 1426 | 0.070 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 36 | 0.070 |
Why?
|
| Respiratory Mucosa | 1 | 2005 | 12 | 0.070 |
Why?
|
| Adult | 6 | 2017 | 9345 | 0.070 |
Why?
|
| Cyclooxygenase 2 | 1 | 2005 | 48 | 0.070 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2005 | 33 | 0.060 |
Why?
|
| Education, Continuing | 1 | 2005 | 6 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 166 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 288 | 0.060 |
Why?
|
| Male | 7 | 2019 | 19165 | 0.060 |
Why?
|
| Female | 7 | 2019 | 19959 | 0.060 |
Why?
|
| Middle Aged | 5 | 2019 | 11817 | 0.060 |
Why?
|
| Transfection | 3 | 2010 | 191 | 0.060 |
Why?
|
| Allergens | 1 | 2002 | 15 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2002 | 46 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 101 | 0.050 |
Why?
|
| Forced Expiratory Volume | 2 | 2013 | 87 | 0.050 |
Why?
|
| Cross-Over Studies | 2 | 2013 | 95 | 0.050 |
Why?
|
| Animals | 4 | 2007 | 7541 | 0.050 |
Why?
|
| Inflammation | 1 | 2005 | 530 | 0.050 |
Why?
|
| Administration, Inhalation | 2 | 2012 | 54 | 0.050 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2017 | 59 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2012 | 525 | 0.040 |
Why?
|
| Epidermal Growth Factor | 2 | 2010 | 27 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2019 | 3306 | 0.040 |
Why?
|
| Interleukin-1beta | 2 | 2008 | 42 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 2 | 2010 | 71 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2010 | 135 | 0.040 |
Why?
|
| Bronchi | 2 | 2011 | 33 | 0.040 |
Why?
|
| Prednisolone | 1 | 2017 | 9 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 545 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2019 | 225 | 0.040 |
Why?
|
| Amino Acid Sequence | 2 | 2005 | 285 | 0.030 |
Why?
|
| Time Factors | 2 | 2010 | 2149 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2013 | 49 | 0.030 |
Why?
|
| Immunoglobulin E | 1 | 2013 | 36 | 0.030 |
Why?
|
| ROC Curve | 1 | 2013 | 164 | 0.030 |
Why?
|
| Breath Tests | 1 | 2012 | 14 | 0.030 |
Why?
|
| Quality of Life | 1 | 2019 | 946 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2012 | 162 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2012 | 111 | 0.020 |
Why?
|
| Bronchial Provocation Tests | 1 | 2011 | 5 | 0.020 |
Why?
|
| Beclomethasone | 1 | 2010 | 2 | 0.020 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2010 | 6 | 0.020 |
Why?
|
| Isoproterenol | 1 | 2010 | 16 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 3990 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2010 | 51 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 67 | 0.020 |
Why?
|
| Mice | 2 | 2007 | 2484 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2010 | 229 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 1497 | 0.020 |
Why?
|
| Autocrine Communication | 1 | 2008 | 7 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2008 | 125 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2008 | 46 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 160 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 114 | 0.020 |
Why?
|
| Phosphatidylinositols | 1 | 2007 | 2 | 0.020 |
Why?
|
| Leukotrienes | 1 | 2007 | 3 | 0.020 |
Why?
|
| Inhalation | 1 | 2007 | 8 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 322 | 0.020 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2007 | 22 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2007 | 48 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 198 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2008 | 508 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2007 | 264 | 0.020 |
Why?
|
| Monocytes | 1 | 2007 | 127 | 0.020 |
Why?
|
| Aged | 1 | 2019 | 10301 | 0.020 |
Why?
|
| Leukotriene D4 | 1 | 2004 | 1 | 0.020 |
Why?
|
| Calcium | 1 | 2007 | 307 | 0.020 |
Why?
|
| COS Cells | 1 | 2004 | 27 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2004 | 20 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2004 | 84 | 0.020 |
Why?
|
| Protein Transport | 1 | 2004 | 74 | 0.020 |
Why?
|
| Kinetics | 1 | 2004 | 209 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2004 | 193 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 359 | 0.010 |
Why?
|
| Young Adult | 1 | 2011 | 2636 | 0.010 |
Why?
|
| Cell Line | 1 | 2004 | 435 | 0.010 |
Why?
|
| Tumor Necrosis Factor Decoy Receptors | 1 | 2002 | 2 | 0.010 |
Why?
|
| Immune Sera | 1 | 2002 | 7 | 0.010 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2002 | 6 | 0.010 |
Why?
|
| Solubility | 1 | 2002 | 36 | 0.010 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2002 | 23 | 0.010 |
Why?
|
| Adolescent | 1 | 2011 | 3539 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2002 | 40 | 0.010 |
Why?
|
| Cell Survival | 1 | 2002 | 284 | 0.010 |
Why?
|
| Cell Movement | 1 | 2002 | 169 | 0.010 |
Why?
|
| Apoptosis | 1 | 2002 | 360 | 0.010 |
Why?
|
| Kidney | 1 | 2004 | 518 | 0.010 |
Why?
|